Evidence map›Paper›PMID 41222022›Full record

ArticleEuropean journal of neurology2025

Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset.

Philipp Klyscz, Klemens Ruprecht, Lina Carlotta Anderhalten, Tanja Schmitz-Hübsch, Jens Kuhle, Tatiana Usnich, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler, Susanna Asseyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Philipp KlysczExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-0058-2365
Klemens RuprechtDivision of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Lina Carlotta AnderhaltenExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
Tanja Schmitz-HübschNeuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0003-4833-5937
Jens KuhleMS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Neurology, Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Tatiana UsnichExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
Judith Bellmann-StroblDepartment of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Friedemann PaulExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
Patrick SchindlerExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
Susanna AsseyerExperimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-6289-1791

Funding

Novartis
6 · The paper itself

Abstract

backgroundWe compared the prognostic value of serum neurofilament light chain (sNFL) and glial fibrillary acidic protein (sGFAP) for clinical and radiologic disease activity among patients with clinically isolated syndrome or early multiple sclerosis (MS) with optic neuritis (pwON) and non-optic neuritis (pwNON) as the first manifestation.

methodsPatients within 7 months (pwON and pwNON) from disease onset and patients with MS with a disease duration longer than 12 months (pwMS) as controls were included. sNFL and sGFAP were analyzed at baseline and at follow-ups using SIMOA technology. Linear mixed models and Cox regression analyses were applied.

resultsWe included 165 samples of 86 patients (18 pwON, 46 pwNON, 21 pwMS). Median follow-up time was 80 months. Mean sNFL z scores were higher in pwNON (1.06) than pwON (0.53) and pwMS (0.94). In pwNON, but not pwON, higher sNFL z scores were associated with an elevated risk for a subsequent attack (pwNON: HR 1.63 [95% CI 1.12 to 2.27], p = 0.005; pwON: HR 0.80 [95% CI 0.51-2.27], p = 0.318) and new MRI T2 lesions (pwNON: HR 1.66 [95% CI 1.31 to 2.11], p < 0.001; pwON: HR 1.16 [95% CI 0.82 to 1.63], p = 0.404). sGFAP z scores were associated with a lower risk of a subsequent attack in pwON (HR 0.34 [95% CI 0.12 to 0.98], p = 0.047).

conclusionsNFL but not sGFAP predicted future clinical and MRI disease activity only in pwNON, potentially suggesting that the prognostic value of sNFL may depend on the type of the first manifestation.

Indexed as

Demyelinating DiseasesMultiple SclerosisNeurofilament ProteinsAdultBiomarkersDisease ProgressionFemaleFollow-Up StudiesGlial Fibrillary Acidic ProteinHumansMagnetic Resonance ImagingMaleMiddle AgedOptic NeuritisPrognosisBiomarkersGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinsbiomarkerglial fibrillary acidic proteinmultiple sclerosisneurofilamentoptic neuritis

Identifiers

PMID41222022
PMCPMC12606448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.